Attend the FierceBiotech 3rd Drug Development Forum!
The leading executive-level forum for biotech strategy & networking | Oct 1-3 | Boston
Tau secretion was thought to be a byproduct of cell death, but new research shows it is an active process.
Scientists at Dana-Farber Cancer Institute and Harvard have invented an immunotherapy “gel” that’s placed at the surgery site and is showing promising results…
Insmed aims to bring a first-in-market therapy to patients in the U.S. suffering from NTM lung disease caused by MAC, a chronic and debilitating condition.
UCSD researchers have developed a small molecule that weakens the virulent H3N2 strain of flu by exploiting a flaw in the mechanism the virus uses to replicate.
Ovarian cancer has proved resistant to immunotherapy, but may be vulnerable to personalized T cell therapy using tumor-derived T cells.
The pair will focus on drugs against the MCL1 protein, which scientists believe is responsible for preventing cancer cell death.
A Tufts University team modeled electrical patterns in frog embryos to find reagents that might reverse birth defects.
Synthetic polymers invented by IBM, which killed five types of superbugs, could be the answer to antibiotic resistance.
Researchers confirmed that the pancreas contains stem cells that can become insulin-producing cells.
Delivering gut microbes to mice can boost antibodies that shield them against sepsis.
Merck's ERK drug had a low response rate but could be used in combinations for BRAF-mutant cancers.